Madrigal's Rezdiffra has received its first FDA approval for the treatment of a form of fatty liver disease, although there is some uncertainty over the specific condition being referred to, with some outlets calling it NASH and others MASH. The approval marks the first drug to be cleared for this condition. The development has generated interest and is seen as a significant step, with potential implications for the market and other companies working on similar treatments.